What is Solriamfetol?
Solriamfetol, also known as Sunosi, is a phenylalanine derivative that acts as a wake-promoting agent. It is formulated as film-coated tablets and has been approved by the US Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. Recently, solriamfetol has been studied for its potential use in treating adult attention-deficit/hyperactivity disorder (ADHD).
The approved uses of solriamfetol mainly focus on sleep disorders such as narcolepsy and sleep apnea.
However, recent studies have suggested that solriamfetol may also be a safe and effective treatment for ADHD in adults. A new study discovered that solriamfetol can reduce ADHD symptoms with no adverse cardiovascular effects. Participants taking solriamfetol in this study experienced fewer ADHD symptoms than those taking a placebo.
These findings suggest that solriamfetol could be a novel and effective treatment for the management of ADHD in adults, but further replication in larger trials is needed to confirm these results.
Solriamfetol is thought to work in the body by increasing levels of dopamine and norepinephrine. Specifically, it is a dopamine and norepinephrine reuptake inhibitor, which means it prevents these neurotransmitters from being reabsorbed back into the nerve cells, thereby increasing their levels in the brain. This increase in dopamine and norepinephrine levels is believed to promote wakefulness and improve attention, which could potentially benefit adults with ADHD.
Benefits and Side Effects of Solriamfetol
Solriamfetol, a medication typically used to treat narcolepsy and sleep apnea, is a potentially effective treatment for adult ADHD. This wakefulness-promoting drug is thought to work by increasing levels of dopamine and norepinephrine in the brain, neurotransmitters that play a key role in attention and focus. A pilot study examining the efficacy of solriamfetol for adult ADHD management found that participants taking the medication experienced a significant reduction in ADHD symptoms compared to those taking a placebo.
These findings suggest that solriamfetol may offer a novel approach to treating ADHD in adults.
While solriamfetol has demonstrated potential benefits for adult ADHD management, it is important to consider its common side effects. Some of the most frequently reported adverse effects associated with solriamfetol use include decreased appetite, headache, nausea, vomiting, and constipation.
Other less common side effects may consist of teeth clenching, weight loss, diarrhea, dizziness, dry mouth, increased sweating, and stomach pain. Although these side effects may be concerning for some individuals, it is worth noting that an online study found solriamfetol to have a good safety profile overall, with significant improvements in ADHD symptoms in adults.
In addition to the common side effects of solriamfetol, there are also serious side effects and precautions that individuals should be aware of when using this medication. Solriamfetol has been shown to cause increased blood pressure and heart rate, which can be dangerous for those with pre-existing cardiovascular conditions. Furthermore, the drug may also lead to psychiatric symptoms such as anxiety, sleep disturbances, and irritability.
It is crucial for individuals considering solriamfetol as a treatment option for adult ADHD to discuss these potential risks with their healthcare provider and carefully weigh the benefits against the potential side effects.
Dosage and Administration of Solriamfetol
The recommended dosages for solriamfetol in treating adult ADHD are based on a dose-optimization trial of 75 mg or 150 mg of solriamfetol. In this trial, researchers randomized 60 adults with ADHD to receive either solriamfetol (75 or 150 mg) or a placebo for six weeks. The participants’ symptoms were assessed using the Adult ADHD Investigator Symptom Rating Scale (AISRS).
The study showed that participants taking solriamfetol experienced a reduction in ADHD symptoms compared to those taking the placebo. Thus, the recommended dosages for solriamfetol in treating adult ADHD are 75 mg or 150 mg.
When taking solriamfetol for adult ADHD, it is important to follow the appropriate dosage and administration guidelines. Solriamfetol is a prescription medicine used to treat the symptoms of narcolepsy and obstructive sleep apnea.
In the context of adult ADHD, solriamfetol has been studied in a double-blind, placebo-controlled pilot study as a new treatment option. The medication weakly binds to dopamine and norepinephrine transporters but not serotonin transporters, and does not bind to dopamine, norepinephrine, or serotonin receptors. Patients should consult with their healthcare provider for specific instructions on how to take solriamfetol, including the appropriate dosage and timing.
It is essential to be aware of potential drug interactions and contraindications when taking solriamfetol for adult ADHD. Although the primary focus of solriamfetol research has been on its use for narcolepsy and sleep apnea, the results from the pilot study suggest that it may be a safe and effective treatment for adult ADHD. However, larger studies are needed to replicate these findings and further explore potential drug interactions and contraindications.
Some adverse events reported with the use of solriamfetol in the trial included headache, insomnia, upper abdominal pain, decreased appetite, and anorexia. Individuals considering solriamfetol as a treatment for ADHD should discuss potential risks and benefits with their healthcare provider to ensure the medication is appropriate for their specific needs.